Apitegromab Cuts Lean Mass Loss by 1.9 kg in 102-Patient GLP-1 Trial
Updated
Updated · spacedaily.com · Aug 5
Apitegromab Cuts Lean Mass Loss by 1.9 kg in 102-Patient GLP-1 Trial
3 articles · Updated · spacedaily.com · Aug 5
Summary
A phase 2 EMBRAZE trial found Apitegromab reduced lean mass loss by 1.9 kilograms in adults taking tirzepatide for weight loss, while total weight loss stayed about the same as with placebo.
102 adults with overweight or obesity were treated for 24 weeks; lean tissue accounted for about 30% of weight lost on placebo versus roughly 15% with the Myostatin-blocking antibody.
The result matters because GLP-1 drugs such as semaglutide and tirzepatide can strip meaningful lean tissue along with fat, a bigger concern for older patients and people near sarcopenia.
Apitegromab offers a potential new use for myostatin blockers after years of failures in muscle-wasting diseases, though the trial showed no measured improvement in physical function and remains only proof of concept.
Could a rare genetic mutation found in unusually strong infants hold the secret to preventing muscle loss during rapid weight-loss therapies?
Will the race to combine modern weight-loss injections with experimental muscle-builders trigger unforeseen metabolic consequences we have yet to understand?
If blocking myostatin successfully builds larger muscles, why are patients failing to show any actual improvements in physical strength or daily function?